Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hirschfeld Oncology
Bethesda, Maryland, United Stateshirschfeldoncology.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hirschfeld Oncology is a clinical-stage biotechnology company specializing in the development of therapies that target the tumor microenvironment, specifically hypoxia-driven pathways. Founded by Dr. Steven Hirschfeld, a former FDA and NIH official, the company focuses on repurposing and optimizing small molecules to treat aggressive cancers like glioblastoma and renal cell carcinoma. Its lead candidate, HO-101, is a small molecule inhibitor of Hypoxia-inducible factor 1-alpha (HIF-1a) designed to disrupt tumor growth and angiogenesis. The company's approach combines deep regulatory insight with innovative clinical trial designs to accelerate the delivery of new treatments to patients.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Hirschfeld Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hirschfeld Oncology.